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The BJD now has a dedicated section for qualitative and outcomes research, and has been a long-
standing supporter of groups developing core outcome sets in dermatology. As such, it is no surprise 
to find the paper by Horbach et al in this month’s BJD1, which outlines the first important steps on 
the journey towards a fully defined core outcome set for vascular malformations (OVAMA project).  
This body of work has much to recommend it.  The team have worked with some of the leading 
groups in the world to develop their methodology including the Core Outcome Measures in 
Effectiveness Trials Initiative (COMET http://www.comet-initiative.org/)2, and the Cochrane Skin 
Group - Core Outcome Set Initiative (CSG-COUSIN http://www.uniklinikum-dresden.de/COUSIN), 
which provides guidance and methodological support for groups wishing to develop core outcome 
sets in dermatology3,4. The team have used the COS-STAR reporting guidelines to ensure 
transparency and completeness of reporting5, and have worked hard to ensure international 
engagement; with input from varied stakeholder groups including dermatology, radiology, plastic 
surgery, as well as patients. 
It is useful to reflect on some of the guiding principles when considering the development of a core 
outcome set for individual conditions.  
Why is international involvement so important? 
The aim of a core outcome set is to harmonise outcomes for use in trials throughout the world so 
that results from different studies can be combined in meta-analyses, and patient care improved 
through better understanding of the available evidence. To achieve this, it is vital that all interested 
parties work together to agree a unified set of outcomes for all future trials. 
Should core sets be developed for different (but similar) conditions? 
Let’s not kid ourselves, developing a core outcome set is A LOT of work.  Are there efficiencies to be 
made in developing a core outcome sets that address a variety of similar conditions?  The OVAMA 
group have explored such potential efficiencies by looking at core domains for three different types 
of vascular malformations within a single core outcome project: lymphatic, venous and 
arteriovenous malformations. Having separate voting for each condition was a brave move, which 
could have resulted in different core domains for each. Happily, this was not the case, and the group 
have been able to identify eight core domains that are relevant across all three conditions (although 
the specific instruments used to measure these domains may differ by condition). 
Why is it important to follow quality standards? 
Developing a core outcome initiative is a big responsibility that should not be underestimated. The 
decisions being made today could well influence trial design and conduct for the next decade or 
more, and so it is incumbent upon those developing core outcome sets to follow the best possible 
methods to achieve consensus. By working with groups such as CSG-COUSIN in the field of 
dermatology, groups can be supported to make informed decisions about best practice in 
developing international consensus agreements. 
So watch this space – you’ll be hearing much more about dermatology core outcome sets in the 
coming years. This is great news for everyone, but especially for patients and healthcare 
professionals wanting to make treatment choices based on the best available evidence. 
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